Skip to main content

LCD L39585: MolDX: Molecular Biomarker Testing for Risk Stratification of Cutaneous Squamous Cell Carcinoma

LCD L39585, MolDX: Molecular Biomarker Testing for Risk Stratification of Cutaneous Squamous Cell Carcinoma, is the Local Coverage Determination that CGS Administrators, LLC applies to claims from 2 states (KY, OH), effective 2026-05-28 and first in force 2024-08-18. The policy text runs 19 words. 3 other contractor versions share this title, so the criteria depend on where the service is furnished. Counting every linked billing and coding article, this one lists 0 covered ICD-10-CM codes: the same total as L39583 (Palmetto GBA, 0 codes, revised 2024-08-18) and the same total as L39589 (Noridian Healthcare Solutions, LLC, 0 codes, revised 2026-01-22).

Compiled from CMS files by the QuickIntell RCM Editorial Team · Data effective · Method: reference methodology · Report a data correction

Data currency: Medicare Coverage Database LCD export: MCD release November 12, 2026 (effective November 8, 2026); Medicare Coverage Database billing and coding articles: MCD release November 12, 2026 (effective November 8, 2026). Next CMS release: weekly, every Thursday.

Contractor
CGS Administrators, LLC
States and territories
2
KY OH
Revision effective
2026-05-28
Original effective
2024-08-18
Policy text
19 words
Covered ICD-10 codes (articles)
0

Where this LCD applies

Each contract number is a jurisdiction on the remittance; the policy binds claims processed under these contracts and no others.

Contracts that apply LCD L39585
ContractContractorTypeStates
15102CGS Administrators, LLCMAC - Part BKY
15202CGS Administrators, LLCMAC - Part BOH
15101CGS Administrators, LLCMAC - Part AKY
15201CGS Administrators, LLCMAC - Part AOH

Coverage indications, limitations and medical necessity

Current molecular biomarker tests that risk stratify individuals with cutaneous squamous cell carcinoma (cSCC) are non-covered by this contractor.

Summary of evidence (opening)

Clinical Background

Cutaneous squamous cell carcinoma (cSCC) is an epidermal keratinocyte-derived malignancy that is the second most common skin cancer. 1,2 Incidence is increasing and varies with latitude in the United States, with higher incidence in areas of greater sun exposure. 3 Each year, over 700,000 new cases are diagnosed, 5600 to 12,600 patients develop nodal metastasis, and there are 4000-8800 deaths. 2,4-7 Incidence is highest in non-Hispanic white populations, greater in males compared to females, and increases with age for a mean age at diagnosis of approximately 71 years. 3 Ultraviolet (UV) radiation due to cumulative and chronic sun exposure is the most important environmental risk factor, occurring more frequently in those with less pigmented skin types. 8-10 In individuals with highly pigmented skin, cSCC is more frequently found on non-sun exposed areas and is often associated with chronic inflammation, chronic wounds, or scarring. 4-7 cSCC of this etiology is more difficult to treat and exhibits a higher recurrence risk. 11-13

The overall prognosis is favorable with a 5-year survival of approximately 98%. 2,8,14 While most tumors are easily cured with surgical excision, a subset result in recurrence, metastasis, and disease-specific death. 14,15 The risk of nodal metastasis ranges from 1.2-5.8% in cohort and tumor registry studies and risk of death is approximately 2%. 14,16,17 In a cohort of patients treated with Mohs micrographic surgery (MMS), the rate of local recurrence was 2.5%, metastatic disease 1.9% and of disease-specific death 0.57%, 18 underscoring the importance of adequate surgical treatment.

Approaches to Risk-Stratification and Staging

The contractor cites 83 sources in the bibliography; the full summary and analysis of evidence are in the CMS record.

Dates, lineage and related policies

Original determination effective
2024-08-18
Current revision effective
2026-05-28
Last reviewed by the contractor
2026-05-11
MCD version
5

Other related documents: A59382 (Billing and Coding), A59822 (Response to Comments).

Using this policy on a claim

Match the documented indication to the covered indications above before the service is scheduled, carry a diagnosis from the article's covered list on the claim line (the diagnosis coverage checker tests one code pair against every article that applies in a state), and keep the elements the documentation section asks for in the record, because the contractor can request it later through medical review. A denial under this policy arrives as CARC 50 with remark N115; the LCD lookup guide walks through the appeal path and the Advance Beneficiary Notice rules, and the CGS Administrators, LLC hub lists every other active policy from the same contractor.

The same policy title at other contractors

Contractors often adopt each other's policies and then revise them separately, so the criteria and the diagnosis lists drift apart. The topic comparison lines up every version.

For teams evaluating QuickIntell software

Where QuickIntell fits with this policy

If your team repeatedly reviews local coverage policies, explore QuickAuth for requirement checks, documentation and status tracking with staff oversight. Confirm the applicable policy, supported workflow and review responsibilities. Use QuickRCM to evaluate the separate claim and denial workflow.

Optional software evaluation, not payer support or help with an individual claim. For coverage or payment decisions, use the official sources on this page. Do not include patient information in a demo booking or inquiry.

Frequently asked questions

What does LCD L39585 cover?

Current molecular biomarker tests that risk stratify individuals with cutaneous squamous cell carcinoma (cSCC) are non-covered by this contractor. The full 19-word policy text is reproduced below from the Medicare Coverage Database export of November 12, 2026.

Which states does LCD L39585 apply to?

CGS Administrators, LLC applies it to Medicare claims in 2 states: KY, OH. It binds only that contractor; 3 other contractor versions of this title govern other jurisdictions, and elsewhere the same service is judged under the local contractor's own policy or, where none exists, claim by claim.

Which diagnosis codes support medical necessity under LCD L39585?

The current export links no billing and coding article with a diagnosis list to LCD L39585, so CGS Administrators, LLC decides coverage on the 19-word policy text and the documentation in the record rather than by an automated diagnosis edit.

How do I appeal a denial under LCD L39585?

A denial under LCD L39585 carries claim adjustment reason code 50 with remark code N115. Compare the documented indication with the policy's covered indications, then file a redetermination with CGS Administrators, LLC within 120 days, record attached. If the service falls outside the policy, bill the patient only with a valid Advance Beneficiary Notice signed before the service.

Sources

Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-11-16. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.

Disclaimer

The policy text and code lists are reproduced from the CMS Medicare Coverage Database export as an operational reference. Verify against the current LCD and article on cms.gov before billing; coverage depends on the full record and the contractor. Not legal, clinical or billing advice.

Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.